XML 165 R38.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Investments in and Advances to Unconsolidated Joint Ventures (Tables)
12 Months Ended
Dec. 31, 2019
Equity Method Investments and Joint Ventures [Abstract]  
Schedule of company owned interests in entities, accounted under equity method

The Company owns interests in the following entities that are accounted for under the equity method (dollars in thousands):
 
 
 
 
 
Carrying Amount
 
 
 
 
 
December 31,
Entity(1)
 
Property Count
Ownership %
 
2019
 
2018
SWF SH JV(2)
 
19
54
 
$
428,258

 
$

CCRC JV(3)
 
15
49
 
325,830

 
365,764

U.K. JV(4)
 
49
 

 
101,735

MBK JV
 
4
50
 
33,415

 
35,435

Other SHOP JVs(5)
 
5
41-90
 
26,876

 
25,493

Medical Office JVs(6)
 
3
20-67
 
9,845

 
10,160

K&Y JVs(7)
 
2
80
 
1,215

 
1,430

Advances to unconsolidated joint ventures, net
 
 
 
 
76

 
71

 
 
 
 
 
$
825,515

 
$
540,088

_______________________________________
(1)
These entities are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.
(2)
In December 2019, the Company formed the SWF SH JV with a sovereign wealth fund. See Note 4 for discussion of the formation of the SWF SH JV.
(3)
See Note 3 for discussion of the 2019 MTCA with Brookdale, including the pending acquisition of Brookdale’s interest in the CCRC JV.
(4)
See Note 4 for discussion of the formation of the U.K. JV in 2018 and subsequent sale of the Company’s equity method investment in 2019.
(5)
In June 2019, the Company acquired the outstanding equity interests in, and began consolidating, the Vintage Park JV (see Note 4). Remaining unconsolidated SHOP joint ventures (and the Company's ownership percentage) include: (i) Waldwick JV (85%); (ii) Otay Ranch JV (90%); (iii) MBK Development JV (50%); (iv) Discovery Naples JV (41%); and (v) Discovery Sarasota JV (47%). The Company’s investments in the Discovery Naples JV and the Discovery Sarasota JV are preferred equity investments earning a 10% per annum fixed-rate return.
(6)
Includes three unconsolidated medical office joint ventures (and the Company’s ownership percentage): (i) Ventures IV (20%); (ii) Ventures III (30%); and (iii) Suburban Properties, LLC (67%).
(7)
At December 31, 2019, includes one unconsolidated joint venture. In October 2019, the Company sold its interest in one of the K&Y joint ventures for $4 million. In January 2020, the Company sold its interest in the remaining K&Y joint venture for $12 million. At December 31, 2018, includes three unconsolidated joint ventures.
The following tables summarize combined financial information for the Company’s unconsolidated joint ventures (in thousands):
 
 
December 31,
 
 
2019
 
2018
Real estate, net
 
$
2,278,743

 
$
2,128,147

Other assets, net
 
511,014

 
479,935

Total assets
 
$
2,789,757

 
$
2,608,082

Mortgage and other debt
 
$
552,824

 
$
827,622

Accounts payable and other
 
591,498

 
655,177

Other partners’ capital
 
756,359

 
515,791

Healthpeak Properties, Inc.'s capital
 
889,076

 
609,492

Total liabilities and partners’ capital
 
$
2,789,757

 
$
2,608,082

 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Total revenues
 
$
523,684

 
$
642,724

 
$
810,216

Total operating expense
 
(381,257
)
 
(492,784
)
 
(643,452
)
Net income (loss)
 
(50,872
)
 
(43,704
)
 
(42,408
)
Healthpeak Properties, Inc.’s share in earnings (losses)
 
(8,625
)
 
(2,594
)
 
10,901

Fees earned by Healthpeak Properties, Inc.
 
169

 
125

 
133

Distributions received by Healthpeak Properties, Inc.
 
47,186

 
48,939

 
81,165